This announcement is unlikely to move the stock materially. Traders should watch for upcoming clinical trial results for izicopan, particularly Phase 2 data in hidradenitis suppurativa or chronic spontaneous urticaria, which would provide more meaningful catalysts.
Price Chart
Executive Summary
InflaRx announced preclinical data for izicopan showing lower reactive metabolite formation compared to avacopan in human liver microsomes. The data are early-stage and in vitro, with no direct clinical implications. This is a routine scientific update with no material financial impact.
Key Facts
- Izicopan demonstrated minimal reactive metabolite formation in a head-to-head in vitro study vs. avacopan.
- Reactive metabolite formation is an early indicator of potential bioactivation-related safety risk.
- Avacopan showed higher levels of thiol adducts, with differences exceeding 100-fold at early time points.
- The company states that in vitro findings do not directly predict clinical outcomes.
- No clinical data, financial guidance, or regulatory milestones were announced.
Financial Impact
No financial impact from this preclinical update.
Risk Factors
- Preclinical data may not translate to clinical safety or efficacy.
- Izicopan is still in development and has no regulatory approvals.
- Competition from approved C5aR inhibitors like avacopan.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001140361-26-018878 |
| Document: ef20072342_6k.htm | 0001140361-26-018878 |
| Document: 0001140361-26-018878-index-headers.html | 0001140361-26-018878 |
| Document: 0001140361-26-018878-index.html | 0001140361-26-018878 |
| Document: 0001140361-26-018878.txt | 0001140361-26-018878 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 6-K | $1.56 | awaiting T+20 | — | $1.58 (+0.96%) |
Oct 22, 2026 4d ago | Press Release | $1.53 | awaiting T+20 | — | $1.58 (+2.94%) |
Oct 2, 2026 24d ago | Press Release | $1.72 | awaiting T+20 | — | $1.58 (−8.43%) |
Oct 1, 2026 25d ago | Press Release | $1.71 | awaiting T+20 | — | $1.58 (−7.89%) |
Aug 14, 2026 10w ago | 424B5 | $2.07 $2.02 | ▲ +2.42% | ▲ +0.44% | $1.58 (+23.91%) |
Aug 13, 2026 10w ago | EFFECT | $2.01 $2.09 | ▼ −3.98% | ▼ −5.73% | $1.58 (+21.64%) |
Aug 6, 2026 11w ago | 6-K | $1.72 $2.23 | ▲ +29.65% | ▲ +29.05% | $1.58 (−8.43%) |
Jun 30, 2026 16w ago | 6-K | $2.33 $1.65 | ▼ −29.18% | ▼ −27.00% | $1.58 (−32.40%) |
Jun 30, 2026 16w ago | Press Release | $2.24 $1.70 | ▼ −24.11% | ▼ −23.08% | $1.58 (−29.69%) |
May 6, 2026 24w ago | 424B5 | $2.65 $2.06 | ▲ +22.26% | ▲ +25.40% | $1.58 (+40.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers